Literature DB >> 20924717

Activity of trabectidin in desmoplastic small round cell tumor.

Ana López-González1, Blanca Cantos, Eva Tejerina, Mariano Provencio.   

Abstract

Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive cancer that typically arises in teenage boys. As a result of its low prevalence, there have been few studies of its treatment and impact on survival. Here, we report the case of a patient who was refractory to multiple drugs but remains stable with trabectedin. To our knowledge, this is the first published report that supports antitumoral activity of trabectedin in DSRCT.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20924717     DOI： 10.1007/s12032-010-9687-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  12 in total

1.  Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.

Authors:  M Tavecchio; C Natoli; P Ubezio; E Erba; M D'Incalci
Journal:  Cell Prolif       Date:  2007-12       Impact factor: 6.831

2.  Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.

Authors:  Ana B Herrero; Cristina Martín-Castellanos; Esther Marco; Federico Gago; Sergio Moreno
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

3.  Intraabdominal desmoplastic small round cell tumors: a diagnostic and therapeutic challenge.

Authors:  Imran Hassan; Roman Shyyan; John H Donohue; John H Edmonson; Leonard L Gunderson; Christopher R Moir; Carola A S Arndt; Antonio G Nascimento; Florencia G Que
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

4.  Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.

Authors:  M Bonfanti; E La Valle; J M Fernandez Sousa Faro; G Faircloth; G Caretti; R Mantovani; M D'Incalci
Journal:  Anticancer Drug Des       Date:  1999-06

5.  Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

Authors:  Daniele Grazziotin Soares; Alexandre E Escargueil; Virginie Poindessous; Alain Sarasin; Aimery de Gramont; Diego Bonatto; João Antonio Pêgas Henriques; Annette K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-26       Impact factor: 11.205

Review 6.  Desmoplastic small round cell tumour: a review of literature and treatment options.

Authors:  C E Stuart-Buttle; C J Smart; S Pritchard; D Martin; I M Welch
Journal:  Surg Oncol       Date:  2008-01-10       Impact factor: 3.279

7.  Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

Authors:  Federica Grosso; Robin L Jones; George D Demetri; Ian R Judson; Jean-Yves Blay; Axel Le Cesne; Roberta Sanfilippo; Paola Casieri; Paola Collini; Palma Dileo; Carlo Spreafico; Silvia Stacchiotti; Elena Tamborini; Juan Carlos Tercero; Josè Jimeno; Maurizio D'Incalci; Alessandro Gronchi; Jonathan A Fletcher; Silvana Pilotti; Paolo G Casali
Journal:  Lancet Oncol       Date:  2007-07       Impact factor: 41.316

8.  Role of homologous recombination in trabectedin-induced DNA damage.

Authors:  M Tavecchio; M Simone; E Erba; I Chiolo; G Liberi; M Foiani; M D'Incalci; G Damia
Journal:  Eur J Cancer       Date:  2008-02-19       Impact factor: 9.162

9.  Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

Authors:  F Grosso; R Sanfilippo; E Virdis; C Piovesan; P Collini; P Dileo; C Morosi; J C Tercero; J Jimeno; M D'Incalci; A Gronchi; S Pilotti; P G Casali
Journal:  Ann Oncol       Date:  2009-05-22       Impact factor: 32.976

10.  Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

Authors:  Claudia Forni; Mario Minuzzo; Emanuela Virdis; Elena Tamborini; Matteo Simone; Michele Tavecchio; Eugenio Erba; Federica Grosso; Alessandro Gronchi; Pierre Aman; Paolo Casali; Maurizio D'Incalci; Silvana Pilotti; Roberto Mantovani
Journal:  Mol Cancer Ther       Date:  2009-02-03       Impact factor: 6.261
View more
  10 in total

1.  Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival.

Authors:  Vivek Subbiah; Salah-Eddine Lamhamedi-Cherradi; Branko Cuglievan; Brian A Menegaz; Pamela Camacho; Winston Huh; Vandhana Ramamoorthy; Pete M Anderson; Raphael E Pollock; Dina C Lev; Wei Qiao; Mary Frances McAleer; Robert S Benjamin; Shreyaskumar Patel; Cynthia E Herzog; Najat C Daw; Barry W Feig; Alexander J Lazar; Andrea Hayes-Jordan; Joseph A Ludwig
Journal:  Clin Cancer Res       Date:  2018-06-05       Impact factor: 12.531

2.  Desmoplastic small round cell tumor: current management and recent findings.

Authors:  Armelle Dufresne; Philippe Cassier; Laure Couraud; Perrine Marec-Bérard; Pierre Meeus; Laurent Alberti; Jean-Yves Blay
Journal:  Sarcoma       Date:  2012-03-29

3.  Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.

Authors:  S Uboldi; I Craparotta; G Colella; E Ronchetti; L Beltrame; S Vicario; S Marchini; N Panini; G Dagrada; F Bozzi; S Pilotti; C M Galmarini; M D'Incalci; R Gatta
Journal:  BMC Cancer       Date:  2017-02-06       Impact factor: 4.430

4.  Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's).

Authors:  Sarah Bétrian; Christophe Bergeron; Jean-Yves Blay; Emmanuelle Bompas; Philippe A Cassier; Laure Chevallier; Jérome Fayette; Magali Girodet; Cécile Guillemet; Axel Le Cesne; Perrine Marec-Berard; Isabelle Ray-Coquard; Christine Chevreau
Journal:  Clin Sarcoma Res       Date:  2017-05-10

5.  Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery?

Authors:  C Honoré; V Atallah; O Mir; D Orbach; G Ferron; C LePéchoux; J B Delhorme; P Philippe-Chomette; S Sarnacki; S Msika; P Terrier; O Glehen; H Martelli; V Minard-Colin; F Bertucci; J Y Blay; S Bonvalot; D Elias; A LeCesne; P Sargos
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

6.  Desmoplastic small round cell tumors: Multimodality treatment and new risk factors.

Authors:  Monika Scheer; Christian Vokuhl; Bernd Blank; Erika Hallmen; Thekla von Kalle; Marc Münter; Rüdiger Wessalowski; Maite Hartwig; Monika Sparber-Sauer; Paul-Gerhardt Schlegel; Christof M Kramm; Udo Kontny; Bernd Spriewald; Thomas Kegel; Sebastian Bauer; Bernarda Kazanowska; Felix Niggli; Ruth Ladenstein; Gustaf Ljungman; Kirsi Jahnukainen; Jörg Fuchs; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak
Journal:  Cancer Med       Date:  2019-01-16       Impact factor: 4.452

7.  Trabectedin for desmoplastic small round cell tumours: a possible treatment option?

Authors:  Anna Maria Frezza; Jeremy S Whelan; Palma Dileo
Journal:  Clin Sarcoma Res       Date:  2014-04-25

8.  Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience.

Authors:  Anna Maria Frezza; Charlotte Benson; Ian R Judson; Saskia Litiere; Sandrine Marreaud; Stefan Sleijfer; Jean-Yves Blay; Raz Dewji; Cyril Fisher; Winette van der Graaf; Larry Hayward
Journal:  Clin Sarcoma Res       Date:  2014-07-29

9.  Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature.

Authors:  Han Hsi Wong; Helen M Hatcher; Charlotte Benson; Omar Al-Muderis; Gail Horan; Cyril Fisher; Helena M Earl; Ian Judson
Journal:  Clin Sarcoma Res       Date:  2013-11-26

10.  Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma.

Authors:  Giacomo G Baldi; Samantha Di Donato; Rossana Fargnoli; Manjola Dona; Rossella Bertulli; Elisabetta Parisi; Lorenzo Fantini; Marta Sbaraglia; Mauro Panella
Journal:  Anticancer Drugs       Date:  2016-10       Impact factor: 2.248
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.